Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Travis Bodeker

Podiatrist, Foot & Ankle Surgery Humble, TX Doctor of Podiatric Medicine

NPI 1457608051 CMS profile 974326

9701 N Sam Houston Pkwy E, Ste 150, Humble, TX 77396

Open in the dashboard

General payments

$7,875

95 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Travis Bodeker of Humble, TX is reported in the CMS Open Payments database as having received $7,875 across 95 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $478 10
2024 General $153 3
2023 General $1,462 22
2022 General $398 6
2021 General $1,771 16
2020 General $1,676 12
2019 General $1,937 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Travis Bodeker
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Travis Bodeker were reported at $478. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Travis Bodeker Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $1,937 $389 $118–$1,406 $163
2020 $1,676 $191 $62–$691 $114
2021 $1,771 $329 $104–$1,341 $132
2022 $398 $419 $125–$1,611 $149
2023 $1,462 $377 $128–$1,164 $160
2024 $153 $394 $134–$1,168 $164
2025 $478 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Treace Medical Concepts, Inc. $2,549 21 payments
  2. Medinc of Texas $1,195 2 payments
  3. Stryker Corporation $888 17 payments
  4. Arthrosurface Incorporated $854 6 payments
  5. Imbed Biosciences Inc. $408 12 payments
  6. Wound Management Technologies, Inc $320 3 payments
  7. Organogenesis Inc. $215 2 payments
  8. Wright Medical Technology, Inc. $166 3 payments
  9. Cook Medical LLC $161 2 payments
  10. Bone Support Inc. $154 1 payment
  11. Other $966 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,270 87 payments
  2. Travel and Lodging $2,439 7 payments
  3. Education $1,166 1 payment
Products named General payments · program years 2019–2025
  1. Lapiplasty System Y $1,681 12 payments
  2. HemiCAP MTP Resurfacing $831 5 payments
  3. LAPIPLASTY SYSTEM Foot And Ankle $786 5 payments
  4. CellerateRx $426 6 payments
  5. AUGMENT INJECTABLE $168 2 payments
  6. Zilver Vena $161 2 payments
  7. CERAMENTBONE VOID FILLER $154 1 payment
  8. VARIAX $153 3 payments
  9. BIO4 $144 1 payment
  10. PROLAYER $135 2 payments
  11. Other $2,162 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

160

Median for Podiatry: 160

Drug cost

$60,702

Median for Podiatry: $2,368

Branded share of claims

11.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Flucytosine Generic 34 $59,741
Terbinafine Hcl Generic 32 $244
Methylprednisolone Sodium Succ Methylprednisolone Sod Succ Brand 19 $212
Methylprednisolone Generic 25 $164
Clotrimazole Generic 17 $144
Diclofenac Sodium Generic 17 $100
Cephalexin Generic 16 $98

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$247,520

Medicare's payments for the services billed

Medicare patients

395

Average age 80

Services billed

1,292

256 women, 139 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 37%
Depression 33%
Heart failure 32%
Ischemic heart disease 31%
Alzheimer's or dementia 31%
Chronic kidney disease 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record